Cargando…
Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
PURPOSE: Hepatocellular carcinoma (HCC) is one of the most common fatal cancers, with no curative therapy available. The concept of ferroptosis is attracting increasing attention in cancer research. Herein, we describe the use of a nanodevice as an effective strategy for inducing ferroptosis to mana...
Autores principales: | Liu, Xianchuang, Zhu, Xinyang, Qi, Xun, Meng, Xianwei, Xu, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884959/ https://www.ncbi.nlm.nih.gov/pubmed/33603367 http://dx.doi.org/10.2147/IJN.S292528 |
Ejemplares similares
-
Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
por: Fadeev, Roman, et al.
Publicado: (2019) -
sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
por: Huang, Ying, et al.
Publicado: (2017) -
Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability
por: Hu, Cuihua, et al.
Publicado: (2018) -
The Antitumour Activity of a Curcumin and Piperine Loaded iRGD-Modified Liposome: In Vitro and In Vivo Evaluation
por: Wang, Yingzheng, et al.
Publicado: (2023) -
An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy
por: Ai, Shichao, et al.
Publicado: (2018)